SXTP 60 Degrees Pharmaceuticals, Inc. - Common Stock
SXTP Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
SXTP Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
SXTP Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
- Strong Buy 2 25.0%
- Buy 4 50.0%
- Hold 2 25.0%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
1 analysts · 2026-08-16Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-1.28 | $-0.78 | -0.50% |
| Dec. 31, 2025 | $-2.34 | $-2.33 | -0.01% |
| Sept. 30, 2025 | $-2.64 | $-4.94 | 2.3% |
| June 30, 2025 | $-5.00 | $-3.92 | -1.1% |
| March 31, 2025 | $-6.24 | $-5.37 | -0.87% |
| Dec. 31, 2024 | $-56.80 | $-16.36 | -40.4% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| SXTP | — | — | — | — | — | — |
| JAGX | — | -0.0 | -1.5% | -465.4% | 907.4% | — |
| JUNS | $35M | -4.1 | — | -39662.8% | 3516.1% | 80.6% |
| ARTL | $2M | -0.1 | — | — | 961.8% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 8 filers · $614K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 3 | 3 | 1 | 3 | — |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Kathmere Capital Management, LLC | $466,576 | 265,100 | 75.99% | Shares |
| CITADEL ADVISORS LLC | $39,357 | 22,362 | 6.41% | Shares |
| XTX Topco Ltd | $31,045 | 17,639 | 5.06% | Shares |
| Kovack Advisors, Inc. | $26,400 | 15,000 | 4.30% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $25,308 | 14,380 | 4.12% | Shares |
| UBS Group AG | $23,922 | 13,592 | 3.90% | Shares |
| BARCLAYS PLC | $1,346 | 765 | 0.22% | Shares |
| OSAIC HOLDINGS, INC. | $44 | 25 | 0.01% | Shares |
Company insiders 7 insiders · 3 officers · 5 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Geoffrey S Dow | President and CEO | Dec. 15, 2025 P | 59,618 | 3 | 0 | $19,942 |
| Tyrone Miller | CFO | Jan. 2, 2025 A | 26,370 | 0 | 0 | $0 |
| Kristen Landon | Chief Operating Officer | Sept. 26, 2024 A | 4,540 | 0 | 0 | $0 |
| Cheryl Xu | Director | June 3, 2025 P | 15,816 | 0 | 0 | $0 |
| Stephen Toovey | Director | May 16, 2024 M | 14,000 | 0 | 0 | $0 |
| Paul Field | Director | May 16, 2024 M | 14,000 | 0 | 0 | $0 |
| Charles W Allen | Director | May 16, 2024 M | 14,000 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only